Hopstem Biotech

News

China's Hopstem has been cleared to move straight to a phase 2 trial in the US for its stem cell-based therapy to aid recovery after a stroke.

News

Shares in Tenax 85% of their value after its drug for patients with pulmonary hypertension caused by a form of heart failure flunked a phase 3 trial.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.